Næste

Automatisk afspilning

Novel targets in the treatment of CTCL

2 Visninger • 08/09/23
Del
Indlejre
administrator
administrator
Abonnenter
0

Jan P. Nicolay, MD, Ruprecht Karls University of Heidelberg, Mannheim, Germany, gives an overview of novel drug targets being investigated for the treatment of cutaneous T-cell lymphoma (CTCL), in particular commenting on the CD30 pathway and the role BCL-2. Dr Nicolay also describes synergistic effect of inhibition of BCL-2 in combination with dimethyl fumarate (DMF). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Vis mere
0 Kommentarer sort Sorter efter
Facebook kommentarer

Næste

Automatisk afspilning